Chandan Healthcare Limited — Investor Meet, 20-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Chandan Healthcare delivered strong Q1 FY27 performance, with consolidated sales of INR 82.26 Cr (up 19.62% YoY) and PAT of INR 7.5 Cr (up 29%). Standalone diagnostics revenue grew 35.85% to INR 49.75 Cr, achieving a robust 36.57% EBITDA margin. The company divested its lower-margin pharmacy business for INR 16.77 Cr to focus solely on diagnostics.

Management is aggressively expanding, targeting 1,000 franchise centers this FY and 3,000 in two years, with minimal company capital. This franchise model offers over 60% margins, contributing to a goal of 40% diagnostic EBITDA. Future plans include 8 new comprehensive centers and a 50%+ top-line growth for diagnostics over three years. Management expressed confidence in its expansion strategy and capital-efficient growth.